Published Date: 15 Apr 2024
One-third of patients experience responses when using adagrasib plus cetuximab, with a median overall survival of 15 points 9 months.
Read Full News1.
Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.
2.
Guideline on management of early-stage non-small cell lung cancer released
3.
Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.
4.
Medical debt in collections persists after cancer diagnosis
5.
Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted
1.
Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases
2.
Unraveling the Complexities of Embryonal Carcinoma: A New Hope for Treatment
3.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
4.
Hemophilia: Pathophysiology, Genetics, and Treatment Advances
5.
Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation